Saturday 7 February 2026

One To Watch

Prologue Medicines

An early-stage biotech studying the viral proteome to develop a pipeline of medicines for a wide range of diseases.

Company Overview

Want to Update your Company's Profile?


Latest Prologue Medicines News

Flagship adds GSK and Merck KGaA deals as pharma interest widens
21 November 2025
Pfizer partners with Flagship’s new spinout Expedition Medicines
23 October 2025
Lila Sciences closes $350m series A to expand AI science platform
15 October 2025
Ajit Singh named CEO of Harbinger Health
15 August 2025
More Prologue Medicines news >


Today's issue

Eikon’s IPO splash fades as shares tumble on debut
article
Eikon’s IPO splash fades as shares tumble on debut
6 February 2026
Biotechnology
Kelun-Biotech expands label in China breast cancer market
6 February 2026
Biotechnology
FDA grants priority review for Hympavzi sBLA
6 February 2026
Biotechnology
Biogen 4th-quarter 2025 results beat forecasts
6 February 2026
Biotechnology
Idorsia progresses lucerastat as a potential oral therapy for Fabry disease
6 February 2026
Pharmaceutical
The Pharma Letter M&A round-up - January 2026
6 February 2026
Biotechnology
Generate: Biomedicines latest to line up IPO
6 February 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze